[go: up one dir, main page]

NO2819265T3 - - Google Patents

Info

Publication number
NO2819265T3
NO2819265T3 NO14169333A NO14169333A NO2819265T3 NO 2819265 T3 NO2819265 T3 NO 2819265T3 NO 14169333 A NO14169333 A NO 14169333A NO 14169333 A NO14169333 A NO 14169333A NO 2819265 T3 NO2819265 T3 NO 2819265T3
Authority
NO
Norway
Application number
NO14169333A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2819265T3 publication Critical patent/NO2819265T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO14169333A 2012-10-12 2014-05-21 NO2819265T3 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261712850P 2012-10-12 2012-10-12

Publications (1)

Publication Number Publication Date
NO2819265T3 true NO2819265T3 (zh) 2018-07-28

Family

ID=49474724

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14169333A NO2819265T3 (zh) 2012-10-12 2014-05-21

Country Status (34)

Country Link
US (1) US9920034B2 (zh)
EP (1) EP2906551B1 (zh)
JP (1) JP6154473B2 (zh)
KR (1) KR102143257B1 (zh)
CN (1) CN104837833B (zh)
AU (1) AU2013329125B2 (zh)
BR (1) BR112015007937A2 (zh)
CA (1) CA2888100A1 (zh)
CL (1) CL2015000916A1 (zh)
CO (1) CO7350621A2 (zh)
CY (1) CY1120238T1 (zh)
DK (1) DK2906551T3 (zh)
EA (1) EA032092B1 (zh)
ES (1) ES2668318T3 (zh)
HR (1) HRP20180465T1 (zh)
HU (1) HUE038272T2 (zh)
IL (1) IL238089B (zh)
LT (1) LT2906551T (zh)
MA (1) MA38071B1 (zh)
MX (1) MX351848B (zh)
MY (1) MY173058A (zh)
NO (1) NO2819265T3 (zh)
NZ (1) NZ707990A (zh)
PE (1) PE20150639A1 (zh)
PH (1) PH12015500678A1 (zh)
PL (1) PL2906551T3 (zh)
PT (1) PT2906551T (zh)
RS (1) RS57039B1 (zh)
SG (1) SG11201502605PA (zh)
SI (1) SI2906551T1 (zh)
SM (1) SMT201800262T1 (zh)
TR (1) TR201807316T4 (zh)
WO (1) WO2014059203A1 (zh)
ZA (1) ZA201503238B (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子xia抑制劑之新穎巨環化合物
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為xia因子抑制劑之環狀p1接合劑
PH12014500625B1 (en) 2011-10-14 2018-12-12 Bristol Myers Squibb Co Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2906541B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2906552B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
ES2712699T3 (es) 2013-03-25 2019-05-14 Bristol Myers Squibb Co Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa
NO2760821T3 (zh) 2014-01-31 2018-03-10
SI3099687T1 (en) 2014-01-31 2018-08-31 Bristol-Myers Squibb Company Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
EP3189047B1 (en) 2014-09-04 2018-12-26 Bristol-Myers Squibb Company Diamide macrocycles that are fxia inhibitors
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
EP3310777B1 (en) 2015-06-19 2019-10-09 Bristol-Myers Squibb Company Diamide macrocycles as factor xia inhibitors
CN107922393A (zh) 2015-07-29 2018-04-17 百时美施贵宝公司 携带非芳族p2,基团的因子xia新大环
EP3328851B1 (en) 2015-07-29 2020-04-22 Bristol-Myers Squibb Company Factor xia macrocyclic inhibitors bearing alkyl or cycloalkyl p2' moieties
CN106496249B (zh) * 2015-09-07 2019-12-13 江苏恒瑞医药股份有限公司 噁唑并吲哚类衍生物、其制备方法及其在医药上的应用
WO2017074833A1 (en) 2015-10-29 2017-05-04 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use
EP3500556B1 (en) 2016-08-22 2023-08-02 Merck Sharp & Dohme LLC Pyridine-1-oxide derivatives and their use as factor xia inhibitors
CN109867660A (zh) * 2017-12-01 2019-06-11 四川科伦博泰生物医药股份有限公司 含季铵离子的四氢异喹啉酰胺化合物及其药物用途
CN111655686B (zh) 2018-03-28 2024-02-09 四川科伦博泰生物医药股份有限公司 四氢异喹啉类衍生物及其制备方法和用途

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7155E (fr) 1906-03-16 1907-05-23 Rene Gabriel Poncet Séchoir rotatif
FR1525186A (fr) 1967-03-29 1968-05-17 Roussel Uclaf Nouvelles pénicillines et procédé de préparation
ATA937274A (de) 1973-12-17 1978-02-15 Thomae Gmbh Dr K Verfahren zur herstellung neuer araliphatischer ketone
DE4034829A1 (de) 1990-11-02 1992-05-07 Merck Patent Gmbh Cyclopeptide
JP3190431B2 (ja) 1991-07-01 2001-07-23 三菱化学株式会社 ケトン誘導体
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
WO1996034010A2 (en) 1995-03-29 1996-10-31 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5624936A (en) 1995-03-29 1997-04-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5869682A (en) 1996-04-03 1999-02-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0891352A4 (en) 1996-04-03 2001-08-16 Merck & Co Inc INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
EP2261232A3 (en) 1998-03-19 2011-04-20 Vertex Pharmaceuticals Incorporated Inhibitors of caspases
EA003640B1 (ru) 1998-05-26 2003-08-28 Варнер-Ламберт Компани Бициклические пиримидины и бициклические 3,4-дигидропиримидины как ингибиторы клеточной пролиферации
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
EP1140878A1 (en) 1999-01-02 2001-10-10 Aventis Pharma Deutschland GmbH Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them ( inhibitio of factor xa activity )
EP1016663A1 (en) 1999-01-02 2000-07-05 Aventis Pharma Deutschland GmbH Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity)
CA2369378A1 (en) 1999-04-09 2000-10-19 Basf Aktiengesellschaft Low-molecular inhibitors of complement proteases
EP1125925A1 (en) 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Amine derivatives for the treatment of apoptosis
MXPA02010452A (es) 2000-05-11 2003-06-06 Bristol Myers Squibb Co Analogos de tetrahidroisoquinolina utiles como secretagogos de la hormona del crecimiento.
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
WO2003011222A2 (en) 2001-07-27 2003-02-13 Merck & Co., Inc. Thrombin inhibitors
US6649606B1 (en) 2001-11-09 2003-11-18 Bristol-Myers Squibb Co. Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
US7138412B2 (en) 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
CA2531796A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
EP1773348A4 (en) 2004-07-12 2009-05-20 Idun Pharmaceuticals Inc TETRA PEPTIDE ANALOGS
WO2006076575A2 (en) 2005-01-13 2006-07-20 Bristol-Myers Squibb Company Substituted biaryl compounds as factor xia inhibitors
US20060183771A1 (en) 2005-02-17 2006-08-17 Seiffert Dietmar A Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors
AU2006311101A1 (en) * 2005-11-11 2007-05-18 F. Hoffmann-La Roche Ag Carbocyclic fused cyclic amines as inhibitors of the coagulation factor Xa
ATE511502T1 (de) 2005-12-14 2011-06-15 Bristol Myers Squibb Co Arylpropionamid-, arylacrylamid-, arylpropinamid- oder arylmethylharnstoffanaloge als faktor-xia- inhibitoren
WO2007070816A2 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Thiophene derivatives as factor xia inhibitors
CN101341124A (zh) 2005-12-14 2009-01-07 布里斯托尔-迈尔斯斯奎布公司 可用作丝氨酸蛋白酶抑制剂的6元杂环
PE20071132A1 (es) 2005-12-23 2007-12-14 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
EP2102189B1 (en) 2006-12-15 2015-07-29 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
PE20081775A1 (es) 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
MX2009012847A (es) 2007-06-13 2009-12-08 Bristol Myers Squibb Co Analogos dipeptidicos como inhibidores de factores de coagulacion.
JP5537442B2 (ja) * 2008-03-13 2014-07-02 ブリストル−マイヤーズ スクイブ カンパニー 第xia因子阻害剤としてのピリダジン誘導体
US8624040B2 (en) 2009-06-22 2014-01-07 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US8513433B2 (en) 2009-07-02 2013-08-20 Angion Biomedica Corp. Small molecule inhibitors of PARP activity
TWI393716B (zh) 2009-08-04 2013-04-21 Merck Sharp & Dohme 作為ixa因子抑制劑之雜環化合物
EP2534154B1 (en) 2010-02-11 2020-08-05 Bristol-Myers Squibb Company Macrocycles as factor xia inhibitors
WO2013009527A2 (en) 2011-07-08 2013-01-17 Merck Sharp & Dohme Corp. Factor ixa inhibitors
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為xia因子抑制劑之環狀p1接合劑
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子xia抑制劑之新穎巨環化合物
CN103987696B (zh) 2011-10-14 2016-12-21 百时美施贵宝公司 作为因子xia抑制剂的取代的四氢异喹啉化合物
PH12014500625B1 (en) * 2011-10-14 2018-12-12 Bristol Myers Squibb Co Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2013055984A1 (en) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
DK2794597T3 (en) 2011-12-21 2018-01-15 Ono Pharmaceutical Co PYRIDINON AND PYRIMIDINON DERIVATIVES AS FACTOR XIA INHIBITORS
WO2013111108A1 (en) 2012-01-27 2013-08-01 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
US20140350034A1 (en) 2012-01-27 2014-11-27 Novartis Ag Aminopyridine derivatives as plasma kallikrein inhibitors
JP2015083542A (ja) 2012-02-08 2015-04-30 大日本住友製薬株式会社 3位置換プロリン誘導体
WO2013167669A1 (en) 2012-05-10 2013-11-14 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
GB201209138D0 (en) 2012-05-24 2012-07-04 Ono Pharmaceutical Co Compounds
EP2876105A4 (en) 2012-07-19 2016-01-13 Sumitomo Dainippon Pharma Co Ltd 1- (CYCLOALKYL-CARBONYL) PROLINE DERIVATIVE
SMT201700240T1 (it) 2012-08-03 2017-07-18 Bristol Myers Squibb Co Diidropiridone-p1 come inibitore del fattore xia
PL2882734T3 (pl) 2012-08-03 2017-05-31 Bristol-Myers Squibb Company Dihydropirydon jako inhibitory czynnika XIA
EP2906552B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2906541B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2014120346A1 (en) 2012-12-19 2014-08-07 Merck Sharp & Dohme Corp. Factor ixa inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
ES2712699T3 (es) 2013-03-25 2019-05-14 Bristol Myers Squibb Co Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa

Also Published As

Publication number Publication date
IL238089B (en) 2019-03-31
AU2013329125A1 (en) 2015-05-28
MA38071B1 (fr) 2017-01-31
LT2906551T (lt) 2018-04-25
US20150266855A1 (en) 2015-09-24
ZA201503238B (en) 2017-11-29
CY1120238T1 (el) 2019-07-10
HK1212333A1 (zh) 2016-06-10
HRP20180465T1 (hr) 2018-05-04
BR112015007937A2 (pt) 2017-07-04
JP6154473B2 (ja) 2017-06-28
CN104837833A (zh) 2015-08-12
WO2014059203A1 (en) 2014-04-17
SG11201502605PA (en) 2015-05-28
HUE038272T2 (hu) 2018-10-29
DK2906551T3 (en) 2018-05-22
CN104837833B (zh) 2017-07-14
KR102143257B1 (ko) 2020-08-10
CO7350621A2 (es) 2015-08-10
PT2906551T (pt) 2018-05-10
MY173058A (en) 2019-12-23
PH12015500678A1 (en) 2015-05-18
KR20150065189A (ko) 2015-06-12
EP2906551B1 (en) 2018-02-28
EA032092B1 (ru) 2019-04-30
SI2906551T1 (en) 2018-05-31
SMT201800262T1 (it) 2018-07-17
TR201807316T4 (tr) 2018-06-21
MX2015004328A (es) 2015-06-10
CA2888100A1 (en) 2014-04-17
ES2668318T3 (es) 2018-05-17
PL2906551T3 (pl) 2018-07-31
AU2013329125B2 (en) 2017-03-30
US9920034B2 (en) 2018-03-20
PE20150639A1 (es) 2015-05-11
EA201590548A1 (ru) 2015-07-30
NZ707990A (en) 2018-07-27
EP2906551A1 (en) 2015-08-19
MX351848B (es) 2017-10-31
MA38071A1 (fr) 2016-06-30
JP2015533168A (ja) 2015-11-19
RS57039B1 (sr) 2018-05-31
CL2015000916A1 (es) 2015-08-14

Similar Documents

Publication Publication Date Title
BR112014017635A2 (zh)
BR112014017614A2 (zh)
BR112014017625A2 (zh)
BR112014017659A2 (zh)
BR112014017592A2 (zh)
BR112014017607A2 (zh)
BR112014017646A2 (zh)
BR112014017638A2 (zh)
AR092201A1 (zh)
BR112013027865A2 (zh)
BR112014017609A2 (zh)
BR112014017644A2 (zh)
BR112014017634A2 (zh)
NO2819265T3 (zh)
BR112014017588A2 (zh)
BR112014013184A8 (zh)
BR112014017618A2 (zh)
BR112014017647A2 (zh)
BR112014017623A2 (zh)
BR112014017630A2 (zh)
BR112014017627A2 (zh)
BR112014017652A2 (zh)
BR112014017621A2 (zh)
BR112014017631A2 (zh)
BR112014017641A2 (zh)